Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02243358 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
A Phase 2 study, sponsored by Henry Ford Health System.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT02243358: Completed Phase 2 study, sponsored by Henry Ford Health System.
NCT02243358 is a Phase 2 study that has completed, run by Henry Ford Health System. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02243358, a Phase 2 study, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
To evaluate the safety and effectiveness of a novel neoadjuvant treatment strategy incorporating 5-fluorouracil/leucovorin with oxaliplatin ( FOLFOX )chemotherapy in combination with chemo-radiation with gemcitabine.
Primary Outcome
Evaluate frequency of achieving R0 resection in patients with resectable and borderline resectable pancreatic cancer treated with a neoadjuvant regimen of FOLFOX followed by RT concurrent with gemcitabine chemotherapy at standard dosing
Interventions
- RADIATION Radiation Therapy
- DRUG Gemcitabine
- DRUG Folfox6
- PROCEDURE Pancreaticoduodenectomy with retroperitoneal lymphadenectomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2014-02 |
| Est. Completion | 2020-01-14 |
| Phase | Phase 2 |
What the finished NCT02243358 record still lists
NCT02243358 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 4 interventions - of which Radiation Therapy is the first listed.
NCT02243358 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02243358 about?
NCT02243358 is a clinical study titled "Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer". To evaluate the safety and effectiveness of a novel neoadjuvant treatment strategy incorporating 5-fluorouracil/leucovorin with oxaliplatin ( FOLFOX )chemotherapy in combination with chemo-radiation with gemcitabine.
What is the current status of trial NCT02243358?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2014-02. Estimated completion is 2020-01-14.
What interventions are being tested in trial NCT02243358?
The interventions under investigation include: Radiation Therapy (RADIATION), Gemcitabine (DRUG), Folfox6 (DRUG), Pancreaticoduodenectomy with retroperitoneal lymphadenectomy (PROCEDURE).
Who is sponsoring clinical trial NCT02243358?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02243358's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia